WFRF:(Bruland P)
Sökning: WFRF:(Bruland P) > Bone-targeted radiu...
- 14 av 15
- Föregående post
- Nästa post
- Till träfflistan
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 07044naa a2200853 4500 | |
| 001 | oai:gup.ub.gu.se/53902 | |
| 003 | SwePub | |
| 008 | 240528s2007 | |||||||||||000 ||eng| | |
| 009 | oai:lup.lub.lu.se:0652b170-3b29-40d4-af31-e0bfe91bee64 | |
| 009 | oai:DiVA.org:umu-54164 | |
| 009 | oai:prod.swepub.kib.ki.se:115688596 | |
| 009 | oai:DiVA.org:liu-49310 | |
| 024 | 7 | a https://gup.ub.gu.se/publication/539022 URI |
| 024 | 7 | a https://doi.org/10.1016/S1470-2045(07)70147-X2 DOI |
| 024 | 7 | a https://lup.lub.lu.se/record/6455622 URI |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-541642 URI |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1156885962 URI |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-493102 URI |
| 040 | a (SwePub)gud (SwePub)lud (SwePub)umud (SwePub)kid (SwePub)liu | |
| 041 | a eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Nilsson, S.u Karolinska Institutet,Karolinska Hospital, Stockholm, Sweden, Karolinska Institute, Stockholm, Sweden4 aut |
| 245 | 1 0 | a Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study |
| 264 | 1 | c 2007 |
| 520 | a BACKGROUND: The alpha-emitter radium-223 ((223)Ra) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone-refractory prostate cancer. We aimed to study mature outcomes from a randomised, multicentre, phase II study of (223)Ra. METHODS: Patients with hormone-refractory prostate cancer and bone pain needing external-beam radiotherapy were assigned to four intravenous injections of (223)Ra (50 kBq/kg, 33 patients) or placebo (31 patients), given every 4 weeks. Primary endpoints were change in bone-alkaline phosphatase (ALP) concentration and time to skeletal-related events (SREs). Secondary endpoints included toxic effects, time to prostate-specific-antigen (PSA) progression, and overall survival. All tests were done at a 5% significance level, based on intention to treat. FINDINGS: Median relative change in bone-ALP during treatment was -65.6% (95% CI -69.5 to -57.7) and 9.3% (3.8-60.9) in the (223)Ra group and placebo groups, respectively (p<0.0001, Wilcoxon ranked-sums test). Hazard ratio for time to first SRE, adjusted for baseline covariates, was 1.75 (0.96-3.19, p=0.065, Cox regression). Haematological toxic effects did not differ significantly between two groups. No patient discontinued (223)Ra because of treatment toxicity. Median time to PSA progression was 26 weeks (16-39) versus 8 weeks (4-12; p=0.048) for (223)Ra versus placebo, respectively. Median overall survival was 65.3 weeks (48.7-infinity) for (223)Ra and 46.4 weeks (32.1-77.4) for placebo (p=0.066, log rank). The hazard ratio for overall survival, adjusted for baseline covariates was 2.12 (1.13-3.98, p=0.020, Cox regression). INTERPRETATION: (223)Ra was well tolerated with minimum myelotoxicity, and had a significant effect on bone-ALP concentrations. Larger clinical trials are warranted to study (223)Ra on the prevention of SREs and on overall survival in patients with hormone-refractory prostate cancer. Bone-targeting properties of (223)Ra could also potentially be used for treating skeletal metastasis from other primary cancers. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
| 653 | a Adenocarcinoma/radiotherapy/secondary | |
| 653 | a Aged | |
| 653 | a Aged | |
| 653 | a 80 and over | |
| 653 | a Alkaline Phosphatase/blood | |
| 653 | a Bone Neoplasms/*radiotherapy/secondary | |
| 653 | a Double-Blind Method | |
| 653 | a *Drug Resistance | |
| 653 | a Neoplasm | |
| 653 | a Humans | |
| 653 | a Male | |
| 653 | a Middle Aged | |
| 653 | a Placebos | |
| 653 | a Prognosis | |
| 653 | a Prostate-Specific Antigen | |
| 653 | a Prostatic Neoplasms/pathology/*radiotherapy | |
| 653 | a Radium/*therapeutic use | |
| 653 | a Survival Rate | |
| 653 | a NATURAL SCIENCES | |
| 700 | 1 | a Franzén, Larsu Franzén, L., Länssjukhuset Sundsvall-Härnösand, Sundsvall, Sweden4 aut0 (Swepub:umu)lafr0004 |
| 700 | 1 | a Parker, C.u Institute of Cancer Research, Royal Marsden Hospital, Sutton, United Kingdom4 aut |
| 700 | 1 | a Tyrrell, C.u Plymouth General Hospital, Plymouth, United Kingdom4 aut |
| 700 | 1 | a Blom, R.u Östergötlands Läns Landsting4 aut |
| 700 | 1 | a Tennvall, Janu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,University Hospital Lund, Lund, Sweden4 aut0 (Swepub:lu)onk-jte |
| 700 | 1 | a Lennernäs, Bo,d 1963u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences,Lennernäs, B., Sahlgrenska University Hospital, Gothenburg, Sweden4 aut0 (Swepub:gu)xlennb |
| 700 | 1 | a Petersson, U.u Centrallasarettet i Västerås, Västerås, Sweden4 aut |
| 700 | 1 | a Johannessen, D. C.u Haukeland University Hospital, Bergen, Norway4 aut |
| 700 | 1 | a Sokal, M.u Nottingham City Hospital, Nottingham, United Kingdom4 aut |
| 700 | 1 | a Pigott, K.u Royal Free Hospital, London, United Kingdom4 aut |
| 700 | 1 | a Yachnin, J.u Karolinska Institutet,Karolinska Hospital, Stockholm, Sweden4 aut |
| 700 | 1 | a Garkavij, Michaelu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,University Hospital Lund, Lund, Sweden4 aut0 (Swepub:lu)onk-mga |
| 700 | 1 | a Strang, P.u Karolinska Institutet,Karolinska Institute, Stockholm, Sweden4 aut |
| 700 | 1 | a Harmenberg, J.u Karolinska Institute, Stockholm, Sweden, Algeta ASA, Oslo, Norway4 aut |
| 700 | 1 | a Bolstad, B.u Algeta ASA, Oslo, Norway4 aut |
| 700 | 1 | a Bruland, O. S.u Bruland, Ø.S., University of Oslo, Norwegian Radium Hospital, Oslo, Norway4 aut |
| 710 | 2 | a Karolinska Institutetb Karolinska Hospital, Stockholm, Sweden, Karolinska Institute, Stockholm, Sweden4 org |
| 773 | 0 | t Lancet Oncolg 8:7, s. 587-594q 8:7<587-94x 1470-2045x 1474-5488 |
| 773 | 0 | t The Lancet Oncologyg 8:7, s. 587-594q 8:7<587-594x 1474-5488 |
| 856 | 4 | u http://dx.doi.org/10.1016/S1470-2045(07)70147-Xy FULLTEXT |
| 856 | 4 8 | u https://gup.ub.gu.se/publication/53902 |
| 856 | 4 8 | u https://doi.org/10.1016/S1470-2045(07)70147-X |
| 856 | 4 8 | u https://lup.lub.lu.se/record/645562 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-54164 |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:115688596 |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-49310 |
- 14 av 15
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Nilsson, S.
- Franzén, Lars
- Parker, C.
- Tyrrell, C.
- Blom, R.
- Tennvall, Jan
- visa fler...
- Lennernäs, Bo, 1 ...
- Petersson, U.
- Johannessen, D. ...
- Sokal, M.
- Pigott, K.
- Yachnin, J.
- Garkavij, Michae ...
- Strang, P.
- Harmenberg, J.
- Bolstad, B.
- Bruland, O. S.
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Cancer och onkol ...
- Artiklar i publikationen
- Lancet Oncol
- The Lancet Oncol ...
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
